Quantx Biosciences closed an oversubscribed $85 million Series B to advance two oral immunology candidates: a STAT6 inhibitor and an IL‑17 inhibitor. The financing will support IND‑enabling work and initiation of clinical trials. Investors cited Quantx’s computational chemistry platform as a driver of the oversubscription. The round underscores continued investor appetite for differentiated small‑molecule immunology approaches despite a cautious funding climate for early‑stage med‑tech.